ITRACONAZOLE by Novartis is clinical pharmacology pharmacokinetics and metabolism: general pharmacokinetic characteristics peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration. Approved for the following fungal infections in immunocompromised, non-immunocompromised patients: 1, the following fungal infections in non-immunocompromised patients: 1. First approved in 2004.
Drug data last refreshed 11h ago
CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism: General Pharmacokinetic Characteristics Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration. As a consequence of non-linear pharmacokinetics, itraconazole accumulates in plasma during…
Worked on ITRACONAZOLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants
Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of Engasertib
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants